Alzheimer’s jab failed to meet goal on reducing memory decline, company says

Previous data had shown that gantenerumab reduced levels of brain amyloid plaque.
Roche has announced disappointing results from drug trials (PA)
PA Archive
Jane Kirby14 November 2022

A new jab for people with early-stage Alzheimer’s has failed to show it can slow down a decline in memory and thinking, according to pharmaceutical giant Roche.

The drug, gantenerumab, is an antibody medicine that held much promise as it entered phase three clinical trials.

However, Roche said the drug, which is given as an injection, could not clearly be shown to slow dementia progression in two drug trials.

While there was some progress, this was not statistically significant. This meant the drug could not be clearly shown to preserve people’s abilities in areas such as remembering, solving problems or personal care.

Previous data had shown that gantenerumab reduces brain amyloid plaque.

Abnormal levels of this naturally occurring amyloid protein clump together in the brains of people with Alzheimer’s, forming plaques that collect between neurons and disrupt cell function.

In September, another drug, lecanemab, was found to slow decline in the memory and thinking of people with early-stage Alzheimer’s.

Alzheimer’s Research UK said those findings represented a “historic moment for dementia research”.

The new clinical studies for Roche included more than 2,000 patients treated for more than two years in more than 30 countries worldwide.

Muriel De Vos, from Roche, said: “We are disappointed that the topline results from the pivotal Phase III Graduate I and II trials show that the primary endpoint of slowing clinical decline has not been met.

“However, we remain committed to transforming the lives of people with Alzheimer’s disease through our ongoing research and development of investigational medicines for different targets, types and stages of AD.”

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in

MORE ABOUT